BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 215 filers reported holding BRIDGEBIO PHARMA INC in Q3 2021. The put-call ratio across all filers is 1.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $18,000 | +12.5% | 1,210 | -32.7% | 0.00% | – |
Q2 2022 | $16,000 | -11.1% | 1,799 | 0.0% | 0.00% | – |
Q1 2022 | $18,000 | -40.0% | 1,799 | 0.0% | 0.00% | – |
Q4 2021 | $30,000 | -64.3% | 1,799 | 0.0% | 0.00% | – |
Q3 2021 | $84,000 | -23.6% | 1,799 | 0.0% | 0.00% | – |
Q2 2021 | $110,000 | -0.9% | 1,799 | 0.0% | 0.00% | – |
Q1 2021 | $111,000 | – | 1,799 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |